文献速递肝胆胰外科胃肠外科

双叶结直肠癌肝转移:不预先清除未来残肝肿瘤的PVE后一期肝切除的肿瘤学安全性

Oncological safety of portal vein embolization without prior tumour clearance in the future liver remnant followed by one-stage hepatectomy for bilateral colorectal liver metastases.
PubMed 文献 · Br J Surg · 2025-01-01

该回顾性队列纳入302例双叶结直肠癌肝转移且未来残肝有肿瘤的患者,比较PVE-OSH、TSH-PVE与ALPPS三种策略。PVE-OSH组无法完成切除的比例为11%,术后肝衰竭、死亡和总生存与另两组相当;肝复发独立危险因素为转移数目和ALPPS。

要点

  • PVE-OSH可用于未来残肝肿瘤负荷有限的患者,避免两步手术。
  • PVE-OSH组11%无法完成切除,低于TSH-PVE的21%,高于ALPPS的4%。
  • 肝复发独立危险因素为转移数目(HR 1.04)和ALPPS(HR 1.64)。

核心结论

  • 对于未来残肝肿瘤负荷有限的双叶结直肠癌肝转移患者,不预先清除未来残肝肿瘤的PVE后一期肝切除可安全实施,从而避免两步手术。

研究设计与样本

  • 回顾性队列研究,纳入2013至2021年间接受肝切除的双叶结直肠癌肝转移且未来残肝有肿瘤的患者302例。
  • 分为三组:PVE-OSH组127例,TSH-PVE组61例,ALPPS组114例。

主要发现

  • ALPPS组肝增生最快,其次为PVE-OSH组。
  • 无法完成成功切除的比例:PVE-OSH组11%,TSH-PVE组21%,ALPPS组4%(P < 0.001)。
  • TSH-PVE组23%在大切除时需额外未来残肝切除/消融。
  • 从首次干预到大切除的中位时间:PVE-OSH组6周(i.q.r. 5-8),TSH-PVE组9周(i.q.r. 7-13),ALPPS组1周(i.q.r. 1-3)(P < 0.001)。
  • 术后肝衰竭、死亡和总生存在三组间相当。

关键数值与推荐

  • 肝复发多变量回归分析:转移数目为独立危险因素(HR 1.04,95% c.i. 1.00至1.07;P = 0.025)。
  • 肝复发多变量回归分析:ALPPS为独立危险因素(HR 1.64,95% c.i. 1.00至2.68;P = 0.048)。

临床怎么用

  • 对于未来残肝肿瘤负荷有限的双叶结直肠癌肝转移患者,可考虑PVE-OSH策略以避免两步手术。
  • 需权衡PVE-OSH组11%无法完成切除的风险与TSH-PVE组21%的风险。

局限性

  • 回顾性队列设计。
  • 除年龄和ECOG体力状态外,其他基线特征具有可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Upfront portal vein embolization (PVE) without prior future liver remnant (FLR) clearing followed by a one-stage hepatectomy (OSH) for bilateral colorectal liver metastases (CRLM) can reduce the surgical burden of a two-stage approach, but oncological safety is not well described and comparisons with alternative two-stage procedures are lacking. METHODS: A retrospective cohort of patients with bilateral CRLM and tumour in the FLR, undergoing liver resection between 2013 and 2021, was studied. The patients were divided into three groups: patients who underwent PVE with no prior tumour clearance in the FLR followed by an OSH (PVE-OSH); patients who underwent tumour clearance in the FLR followed by PVE (TSH-PVE; where TSH stands for two-stage hepatectomy); and patients who underwent associating liver partition and portal vein ligation for staged hepatectomy (ALPPS). RESULTS: In total, 302 patients with bilateral CRLM were included, of whom 127 underwent PVE-OSH, 61 underwent TSH-PVE, and 114 underwent ALPPS. Except for age and Eastern Cooperative Oncology Group (ECOG) Performance Status, all baseline characteristics were comparable. The most rapid hypertrophy was experienced by ALPPS patients, followed by PVE-OSH patients. Successful resection could not be performed in 11% of PVE-OSH patients, 21% of TSH-PVE patients, and 4% of ALPPS patients (P < 0.001). During major resection, 23% of TSH-PVE patients required additional FLR resection/ablation and the median time from first intervention to major resection was 9 (interquartile range (i.q.r.) 7-13) weeks, compared with 6 (i.q.r. 5-8) weeks for PVE-OSH patients and 1 (i.q.r. 1-3) week for ALPPS patients (P < 0.001). Postoperative outcomes were comparable regarding liver failure, mortality, and overall survival. Multivariable regression analysis for liver recurrence identified the number of metastases (HR 1.04 (95% c.i. 1.00 to 1.07); P = 0.025) and ALPPS (HR 1.64 (95% c.i. 1.00 to 2.68); P = 0.048) as independent risk factors. CONCLUSION: PVE-OSH can be performed safely for patients with a limited tumour burden in the FLR, thereby obviating the need for two-stage procedures.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Reese T, Björk D, Longva AMH, et al. Oncological safety of portal vein embolization without prior tumour clearance in the future liver remnant followed by one-stage hepatectomy for bilateral colorectal liver metastases. Br J Surg. 2025. PMID: 40982475. doi:10.1093/bjs/znaf198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。